UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335. Amgen reported in-line topline sales for Q3, with most products as ...

Amgen (NASDAQ:AMGN – Free Report) had its target price cut by UBS Group from $335.00 to $326.00 in a report released on Thursday, Benzinga reports. They currently have a neutral rating on the medical ...

UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335 ... offset by higher Nplate, Blincyto, and Repatha sales, the analyst tells investors in a research note.

AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.

My name is Julianne, and I will be your conference facilitator today for Amgen ... Nplate sales grew 18% year-over-year for the third quarter, driven by 14% volume growth and higher net selling price.

Other products are Repatha, Blincyto, Vectibix, Nplate, Kyprolis ... rating. Shares of Amgen are trading at a forward earnings multiple of 16.4X, as well as a PEG Ratio of 2.8, a Price/Cash Flow ratio ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible assets ...

As we can see, the immunology drug Enbrel, osteoporosis drug Prolia, bone tumor therapy Xgeva, thrombocytopenia therapy Nplate ... data would have on Amgen's share price, because of the size ...

The new price target represents a valuation ... This forecast is based on the performance of several of Amgen's key franchises, including Enbrel, Nplate, Repatha, Otezla, Mvasi, Tezspire, and ...